FindMyKOL
Clinical trialNCT03132584TerminatedPhase 1Interventional

Cyclophosphamide and Alemtuzumab In Lymphoma

SponsorDana-Farber Cancer InstituteEnrollment3Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaNon Hodgkin Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: * Cyclophosphamide * Alemtuzumab

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jul 2017
Primary completion
30 Jan 2018
Completion
30 Jan 2018
Last update posted
14 Jan 2019
Registered enrollment
3
Registry id
NCT03132584

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.